GFM
TNGX icon

GF Fund Management’s Tango Therapeutics TNGX Stock Holding History

GF Fund Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63K Buy
3,011
+365
+14% +$5.08K ﹤0.01% 378
2025
Q4 		$23.4K Buy
2,646
+252
+11% +$2.17K ﹤0.01% 489
2025
Q3 		$20.1K Sell
2,394
-271
-10% -$1.83K ﹤0.01% 485
2025
Q2 		$13.6K Hold
2,665
– – ﹤0.01% 537
2025
Q1 		$3.65K Buy
2,665
+410
+18% +$1.01K ﹤0.01% 635
2024
Q4 		$6.97K Buy
+2,255
New +$10.5K ﹤0.01% 589

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

GF Fund Management's TNGX Position: Q1 2026 in Review

GF Fund Management increased its Tango Therapeutics (TNGX) stake by 14% in Q1 2026, buying an estimated $5.08K and bringing the position to 3,011 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #378.

GF Fund Management first reported a position in TNGX in Q4 2024 and has held it in 6 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • GF Fund Management held 3,011 shares of Tango Therapeutics worth $63K as of Q1 2026.
  • GF Fund Management bought 365 Tango Therapeutics shares in Q1 2026, an estimated $5.08K.
  • Tango Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #378 holding.
  • GF Fund Management first reported a position in Tango Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.